Venoty&L: "Venobio Registers Patent for Next-Generation Injectable Composition for Macular Degeneration Treatment"

Venobio, a new drug development company affiliated with KOSDAQ-listed Venoty&L (CEO Han Seung-il), announced on June 16 that it has completed the final registration of a domestic patent for an injectable composition for the prevention or treatment of ocular diseases containing a carboxamide derivative as an active ingredient.

The newly registered patent covers technology related to an injectable composition and ophthalmic formulation that maximizes intraocular drug delivery efficiency and enhances stability. This is significant as it not only officially recognizes the pharmaceutical completeness and differentiated formulation technology of Venobio’s core pipeline under development, but also establishes an exclusive technological barrier for future entry into the global market.

This patented technology is closely linked to the key formulation technology of “BBRP11001,” Venobio’s macular degeneration treatment currently undergoing Phase 1 clinical trials in Australia. Since formulation technology that enables drugs to maintain stable efficacy in the eye over an extended period is considered a core competitive edge for ocular disease treatments, this patent registration is expected to further increase the likelihood of successful clinical outcomes in Australia and secure an advantageous position in technology transfer (L/O) negotiations with global big pharma companies.

The company plans to accelerate patent applications and registrations in major overseas markets (the United States, Europe, Japan, etc.), starting with this domestic patent registration, to solidify its exclusive position in the global market.

Lee Inhyeon, Vice President of Venobio, stated, “With the Phase 1 clinical trial of BBRP11001 in Australia progressing smoothly, this patent acquisition has further cemented our exclusive rights in the global market. We will leverage Venobio’s differentiated new drug development capabilities and unique IP (intellectual property) competitiveness to achieve early global partnership results.”

Meanwhile, Venobio continues to achieve visible results across a diverse pipeline, including oncology and ocular diseases. Recently, its AI-based Pan-KRAS inhibitor (BBRP11031) development project was selected for the “2026 Global Enterprise Collaboration Program (Dassault Systemes Daonda Program)” hosted by the Ministry of SMEs and Startups.

This content was produced with the assistance of AI translation services.